Literature DB >> 18580547

Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review.

Pepijn D D M Roelofs1, Rick A Deyo, Bart W Koes, Rob J P M Scholten, Maurits W van Tulder.   

Abstract

STUDY
DESIGN: A systematic review of randomized controlled trials.
OBJECTIVES: To assess the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors in the treatment of nonspecific low back pain and to assess which type of NSAID is most effective. SUMMARY OF BACKGROUND DATA: NSAIDs are the most frequently prescribed medications worldwide and are widely used for patients with low back pain. Selective COX-2 inhibitors are currently available and used for patients with low back pain.
METHODS: We searched the MEDLINE and EMBASE databases and the Cochrane Central Register of Controlled Trials up to and including June 2007 if reported in English, Dutch, or German. We also screened references given in relevant reviews and identified trials. Randomized trials and double-blind controlled trials of NSAIDs in nonspecific low back pain with or without sciatica were included.
RESULTS: In total, 65 trials (total number of patients = 11,237) were included in this review. Twenty-eight trials (42%) were considered high quality. Statistically significant effects were found in favor of NSAIDs compared with placebo, but at the cost of statistically significant more side effects. There is moderate evidence that NSAIDs are not more effective than paracetamol for acute low back pain, but paracetamol had fewer side effects. There is moderate evidence that NSAIDs are not more effective than other drugs for acute low back pain. There is strong evidence that various types of NSAIDs, including COX-2 NSAIDs, are equally effective for acute low back pain. COX-2 NSAIDs had statistically significantly fewer side effects than traditional NSAIDs.
CONCLUSION: The evidence from the 65 trials included in this review suggests that NSAIDs are effective for short-term symptomatic relief in patients with acute and chronic low back pain without sciatica. However, effect sizes are small. Furthermore, there does not seem to be a specific type of NSAID, which is clearly more effective than others. The selective COX-2 inhibitors showed fewer side effects compared with traditional NSAIDs in the randomized controlled trials included in this review. However, recent studies have shown that COX-2 inhibitors are associated with increased cardiovascular risks in specific patient populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580547     DOI: 10.1097/BRS.0b013e31817e69d3

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  59 in total

1.  Diagnostic testing and treatment of low back pain in United States emergency departments: a national perspective.

Authors:  Benjamin W Friedman; Mikaela Chilstrom; Polly E Bijur; E John Gallagher
Journal:  Spine (Phila Pa 1976)       Date:  2010-11-15       Impact factor: 3.468

2.  A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain.

Authors:  Benjamin W Friedman; David Cisewski; Eddie Irizarry; Michelle Davitt; Clemencia Solorzano; Adam Nassery; Scott Pearlman; Deborah White; E John Gallagher
Journal:  Ann Emerg Med       Date:  2017-10-28       Impact factor: 5.721

3.  Validation of a risk factor-based intervention strategy model using data from the readiness for return to work cohort study.

Authors:  Ivan A Steenstra; Selahadin A Ibrahim; Renée-Louise Franche; Sheilah Hogg-Johnson; William S Shaw; Glenn S Pransky
Journal:  J Occup Rehabil       Date:  2010-09

Review 4.  Molecular basis of intervertebral disc degeneration and herniations: what are the important translational questions?

Authors:  Tiffany Kadow; Gwendolyn Sowa; Nam Vo; James D Kang
Journal:  Clin Orthop Relat Res       Date:  2015-06       Impact factor: 4.176

5.  Are non-steroidal anti-inflammatory drugs effective for the management of neck pain and associated disorders, whiplash-associated disorders, or non-specific low back pain? A systematic review of systematic reviews by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration.

Authors:  Jessica J Wong; Pierre Côté; Arthur Ameis; Sharanya Varatharajan; Thepikaa Varatharajan; Heather M Shearer; Robert J Brison; Deborah Sutton; Kristi Randhawa; Hainan Yu; Danielle Southerst; Rachel Goldgrub; Silvano Mior; Maja Stupar; Linda J Carroll; Anne Taylor-Vaisey
Journal:  Eur Spine J       Date:  2015-04-01       Impact factor: 3.134

6.  PURLs: More isn't better with acute low back pain treatment.

Authors:  Kevin Frazer; James J Stevermer
Journal:  J Fam Pract       Date:  2016-06       Impact factor: 0.493

7.  Development of an Experimental Animal Model for Lower Back Pain by Percutaneous Injury-Induced Lumbar Facet Joint Osteoarthritis.

Authors:  Jae-Sung Kim; Kasra Ahmadinia; Xin Li; John L Hamilton; Steven Andrews; Chris A Haralampus; Guozhi Xiao; Hong-Moon Sohn; Jae-Won You; Yo-Seob Seo; Gary S Stein; Andre J Van Wijnen; Su-Gwan Kim; Hee-Jeong Im
Journal:  J Cell Physiol       Date:  2015-11       Impact factor: 6.384

8.  Limaprost alfadex and nonsteroidal anti-inflammatory drugs for sciatica due to lumbar spinal stenosis.

Authors:  Akira Onda; Shin-Ichi Kikuchi; Shoji Yabuki; Koji Otani; Takuya Nikaido; Kazuyuki Watanabe; Shin-Ichi Konno
Journal:  Eur Spine J       Date:  2012-10-23       Impact factor: 3.134

9.  Pharmacologic management of chronic pain.

Authors:  Hue Jung Park; Dong Eon Moon
Journal:  Korean J Pain       Date:  2010-05-31

10.  Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain.

Authors:  Carlo Luca Romanò; Delia Romanò; Cristina Bonora; Giuseppe Mineo
Journal:  J Orthop Traumatol       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.